News from vicore pharma holding ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 07, 2022, 22:07 ET Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), has...

Dec 07, 2022, 12:09 ET Vicore intends to carry out a directed share issue

Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

Dec 05, 2022, 02:43 ET Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

Vicore Pharma Holding AB (publ) ("Vicore"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), today launched the...

Nov 03, 2022, 12:59 ET Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

Nov 03, 2022, 12:58 ET Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

Oct 06, 2022, 03:06 ET Vicore's digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

Vicore Pharma Holding AB (publ) ('Vicore') pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive...

Oct 06, 2022, 03:04 ET Vicore's digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

Vicore Pharma Holding AB (publ) ('Vicore') pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive...

Sep 22, 2022, 02:18 ET Vicore announces that C21 promotes vascular function in humans

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines stimulating the angiotensin II type 2...

Aug 17, 2022, 02:14 ET Vicore IPF interim data selected as an oral "late-breaker" at the ERS congress

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor ...

Jun 16, 2022, 02:14 ET Vicore announces first human dosed with novel ATRAG, C106

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor ...

Apr 21, 2022, 03:47 ET Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot phase of ...

Mar 09, 2022, 02:28 ET Vicore strengthens rare lung disease pipeline with PAH indication

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2 receptor ...

Mar 04, 2022, 04:38 ET Vicore to host R&D Day

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor ...

Feb 23, 2022, 02:46 ET Vicore takes major step towards a clinical platform company targeting AT2R - new molecule ready for phase 1

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor ...

Feb 10, 2022, 01:15 ET Vicore's AIR study interim analysis suggests that C21 improves lung function in IPF patients

Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor ...

Nov 04, 2021, 03:43 ET Interim report July - September 2021

Important events during the third quarter In August, Vicore announced a strenghtened management team with three senior recruitments; Jessica Shull,...

Nov 02, 2021, 03:13 ET Vicore's C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today...

Oct 25, 2021, 02:39 ET Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today...

Sep 22, 2021, 03:22 ET Vicore To Host Key Opinion Leader Webinar On C21 For The Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders such as...

Sep 22, 2021, 02:25 ET Vicore obtains SARS coronavirus patent for C21 in the USA

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today...

Sep 17, 2021, 03:06 ET Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today...

Aug 26, 2021, 03:21 ET Interim report April - June 2021

Important events during the second quarter In May, Vicore1 announced that it had entered into a collaboration agreement with Alex Therapeutics for...

Jun 15, 2021, 02:44 ET Vicore announces participation in investor meetings during June 2021

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as ...

Jun 11, 2021, 02:46 ET Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as ...

May 05, 2021, 02:31 ET Interim report January - March 2021: Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2021. Important events during the first quarter In February,...